Fusion Pharmaceuticals (FUSN) Short Interest Ratio & Short Volume

Short interest is the volume of Fusion Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 272,900 shares of FUSN short. Learn More on Fusion Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FUSN shares currently have a short interest ratio of 4.0. Learn More on Fusion Pharmaceuticals's short interest ratio.

Fusion Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 272,900 shares, an increase of 1.7% from the previous total of 268,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Fusion Pharmaceuticals: Sutro Biopharma, Inc. (5.15%), Cabaletta Bio, Inc. (12.69%), Caribou Biosciences, Inc. (14.00%), ProKidney Corp. (11.64%), NanoString Technologies, Inc. (10.06%), SOPHiA GENETICS SA (0.20%), Kodiak Sciences Inc. (3.24%), Innate Pharma S.A. (0.08%), Scholar Rock Holding Co. (7.18%), X4 Pharmaceuticals, Inc. (2.41%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks.

Short selling FUSN is an investing strategy that aims to generate trading profit from Fusion Pharmaceuticals as its price is falling. FUSN shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Fusion Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FUSN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FUSN, twice per month. The most recent reporting period available is May, 15 2023.